Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

177Lu-ACT319 in FAP Expressing Solid Tumors

10 listopada 2026 zaktualizowane przez: Actithera INC.

A Phase 1/2 Study of 177Lu-ACT319 in Patients With Advanced FAP Expressing Solid Tumors

This is a study of 177Lu -ACT319 in participants with the following cancers: pancreatic ductal adenocarcinoma (PDAC), biliary tract carcinoma (BTC), that is advanced, and for which there are no valid treatment options. Participants must have cancer that expresses protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, how the body tolerates, and how well ACT319 works in treating cancer. In addition, this study will evaluate how much 177Lu-ACT319 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last approximately 2 years.

A separate group of patients with other FAP expressing solid tumor types will be evaluated by PET/CT or SPECT/CT imaging for the intensity of target expression.

Przegląd badań

Szczegółowy opis

Part 1A evaluates escalating 177Lu-ACT319 doses in PDAC/BTC to estimate MTD and/or define RDE.

Part 1B is an open-label single-arm exploratory imaging sub-study in other FAP-expressing tumors.

Part 2A randomizes patients with PDAC 1:1 between Recommended Dose for Expansion (RDE and RDE-1 dose levels) to identify an optimized dose regimen/RP2D.

Part 2B may expand at the optimized dose in additional solid tumors selected from emerging data. FAP-positive disease is confirmed by PET/SPECT imaging. Treatment is IV administration every 6 weeks for up to 4 cycles, with up to 2 optional additional cycles based on benefits/safety.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

182

Faza

  • Faza 2
  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

  • Nazwa: Head of Clinical Operations
  • Numer telefonu: +1-617-780-8045
  • E-mail: info@actithera.com

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Male and female participants, age ≥ 18 years on the day of signing informed consent.
  • Histologically of cytologically confirmed advanced, unresectable and/or metastatic cancer. Participants must be refractory to or not tolerant to existing therapies known to provide clinical benefits for their condition
  • At least one measurable lesion per RECIST v1.1 by investigator assessment.
  • FAPI PET/SPECT imaging positive.
  • Adequate organ and bone marrow function in the 7 days prior to treatment.
  • Patient Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Anticipated life expectancy of 6 months or higher in the opinion of the investigator.
  • Participants with known central nervous system (CNS) metastasis will be eligible if they are clinically stable.

Exclusion Criteria:

  • Known hypersensitivity to the active substance, or to any of the excipients of the 177Lu-ACT319.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, uncontrolled diabetes mellitus, symptomatic congestive heart failure, or unstable angina pectoris.
  • Participants who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 - Active clinically significant cardiac disease
  • Any major surgery within 4 weeks before enrollment. - Pregnancy or breastfeeding. - Unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, study procedures, and contraception requirements. - Known diagnosis of liver cirrhosis, systemic fibrotic condition such as pulmonary fibrosis, retroperitoneal fibrosis, etc.
  • Any concurrent systemic antineoplastic therapy for the underlying disease and/or other investigational agents within a period which is ≤ 5 t1/2 or ≤ 2 weeks (whichever is longer) prior to the first injection of 177Lu-ACT319 (C1D1).
  • Treatment with any radiopharmaceutical within 6 weeks of Investigational medicinal product (IMP) or 10 half-lives, whatever is longer.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nielosowe
  • Model interwencyjny: Zadanie sekwencyjne
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: 177Lu-ACT319 dose escalation (Part 1A)

In part 1A (dose escalation) - PDAC and BTC will be enrolled

At Dose level 1

At Dose Level 2

At Dose Level 3

At Dose Level 4

Eksperymentalny: FAP-targeted PET/CT or SPECT/CT imaging (Part 1B)

In part 1B Exploratory imaging cohort to characterize FAP expression across multiple tumor types (different from PDAC/BTC) expressing FAP.

Low Dose [18F]-FAPI-74 for PET/CT imaging in Part 1B

Low Dose 177Lu-ACT319 for imaging in Part 1B

Eksperymentalny: 177Lu-ACT319 dose optimization and expansion (Part 2A)

In part 2A; Patients with pancreatic ductal carcinoma will be enrolled for dose optimization and expansion.

177Lu-ACT319 at Recommended Dose for Expansion

177Lu-ACT319 at one level lower than at Recommended Dose for Expansion

Eksperymentalny: 177Lu-ACT319 dose expansion (Part 2B)

In 2B: patients with other solid tumors expressing FAP will be enrolled for dose expansion.

177Lu-ACT319 at Recommended Dose for Expansion

177Lu-ACT319 at one level lower than at Recommended Dose for Expansion

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Dose escalation (Part 1A)
Ramy czasowe: First 42 days of Cycle 1

Incidence of Dose limiting Toxicities (DLTs.)

First 42 days of Cycle 1
Imaging/Dosimetry Sub-study (Part 1B)
Ramy czasowe: 2 days post drug administration

Ratio of Standardized Uptake Value (SUV) to reference region SUV measured using PET/SPECT imaging.

2 days post drug administration
Dose optimization and expansion (Part 2A/2B)
Ramy czasowe: Up to 12 months after the last treatment.

Objective Response Rate (ORR) defined as the percentage of participants who achieve a PR or CR to therapy locally assessed by the investigator as measured by RECIST v1.1.

Up to 12 months after the last treatment.
Dose escalation (Part 1A)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Type, Frequency and severity of Adverse events and SAEs in all patients who received at least one dose of the study drug.

Up to 24 months from the first treatment cycle administration.
Imaging/Dosimetry Sub-study (Part 1B)
Ramy czasowe: Up to 8 days.

Type, frequency and severity of AEs and SAEs.

Up to 8 days.
Dose escalation (Part 1A)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Frequency and duration of dose delays, dose interruptions, and dose reductions.

Up to 24 months from the first treatment cycle administration.
Vital Signs: Change from baseline in systolic blood pressure (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg).

Up to 8 days.
Vital Signs: Change from baseline in diastolic blood pressure (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg).

Up to 8 days.
Vital Signs: Change from baseline in pulse rate (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in pulse rate, measured in beats per minute.

Up to 8 days.
Vital Signs: Change from baseline in respiratory rate (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in respiratory rate, measured in breaths per minute.

Up to 8 days.
Vital Signs: Change from baseline in body temperature (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in body temperature, measured in degrees Celsius.

Up to 8 days.
ECGs: Change from baseline in ECG heart rate (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in heart rate, recorded using a 12-lead electrocardiogram (ECG) and measured in beats per minute.

Up to 8 days.
ECGs: Change from baseline in ECG PR interval (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in PR interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 8 days.
ECGs: Change from baseline in ECG QRS duration (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in QRS duration, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 8 days.
ECGs: Change from baseline in ECG QT interval (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in QT interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 8 days.
Imaging sub-study (Part 1B): Number of participants with clinically significant laboratory abnormalities
Ramy czasowe: Up to 8 days.

Number of participants with at least one new or worsened clinically significant abnormality from baseline in hematology, biochemistry, coagulation or other applicable safety laboratory test as assessed by the investigator. Each participant is counted once, regardless of the number of qualifying abnormalities or assessment visits.

Up to 8 days.
ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1B)
Ramy czasowe: Up to 8 days.

Change from baseline in QT interval corrected for heart rate using Fridericia's formula, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds

Up to 8 days.
Dose escalation (Part 1A)
Ramy czasowe: First 42 days of Cycle 1

MTD and/or RDE as determined by the BOIN dose-escalation algorithm based on observed DLT rates.

First 42 days of Cycle 1
Vital Signs: Change from baseline in systolic blood pressure (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg).

Up to 24 months from the first treatment cycle administration.
Vital Signs: Change from baseline in diastolic blood pressure (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg).

Up to 24 months from the first treatment cycle administration.
Vital Signs: Change from baseline in pulse rate (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in pulse rate, measured in beats per minute.

Up to 24 months from the first treatment cycle administration.
Vital Signs: Change from baseline in respiratory rate (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in respiratory rate, measured in breaths per minute.

Up to 24 months from the first treatment cycle administration.
Vital Signs: Change from baseline in body temperature (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in body temperature, measured in degrees Celsius.

Up to 24 months from the first treatment cycle administration.
ECGs: Change from baseline in ECG heart rate (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in heart rate, recorded using a 12-lead electrocardiogram (ECG) and measured in beats per minute.

Up to 24 months from the first treatment cycle administration.
ECGs: Change from baseline in ECG PR interval (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in PR interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 24 months from the first treatment cycle administration.
ECGs: Change from baseline in ECG QRS duration (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in QRS duration, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 24 months from the first treatment cycle administration.
ECGs: Change from baseline in ECG QT interval (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in QT interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 24 months from the first treatment cycle administration.
ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in QT interval corrected for heart rate using Fridericia's formula, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 24 months from the first treatment cycle administration.
ECOG: Change from baseline in ECOG performance status (Part 1A, 2A, 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance-status score. Scores range from 0 to 5, with higher scores indicating worse performance status.

Up to 24 months from the first treatment cycle administration.
Dose Escalation (Part 1A): Number of participants with clinically significant laboratory abnormalities
Ramy czasowe: Up to 24 months from the first treatment cycle administration

Number of participants with at least one new or worsened clinically significant abnormality from baseline in hematology, biochemistry, coagulation or urinalysis tests, as assessed by the investigator. Each participant is counted once regardless of the number of qualifying abnormalities or assessment visits.

Up to 24 months from the first treatment cycle administration
Dose optimization and expansion (Part 2A)
Ramy czasowe: Up to 24 months.

Selection of the dose regimen with the most favorable overall benefit-risk profile among the dose levels evaluated in Part 2A (RP2D).

Up to 24 months.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Dose escalation (Part 1A): Maximum observed blood concentration (Cmax) of total ACT319.
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Maximum observed blood concentration (Cmax) of total ACT319 in blood derived from the blood concentration time data

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A): Time of the peak of blood concentration (Tmax) of total ACT319.
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Time after administration to the maximum observed concentration of total ACT319 in blood.

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A): Blood concentration plotted against time (AUC) of total ACT319.
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Area under the total ACT319 blood concentration time curve

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A): Blood Elimination time for ACT319 (t1/2).
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Terminal elimination half-life of total ACT319 derived from the blood concentration time data.

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A): Maximum observed blood radioactivity concentration (Cmax) of 177Lu-ACT319.
Ramy czasowe: Cycle 1: Up to Day 8 post-dose.

Maximum observed radioactivity concentration in blood following administration of 177Lu-ACT319

Cycle 1: Up to Day 8 post-dose.
Dose escalation (Part 1A): Time to maximum observed blood radioactivity concentration (Tmax) of 177Lu-ACT319.
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Time after administration of 177Lu-ACT319 to the maximum observed radioactivity concentration in blood

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A): Area under the blood radioactivity concentration curve (AUC) of total 177Lu-ACT319.
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Area under the blood radioactivity concentration time curve following administration of 177Lu-ACT319.

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A): Elimination half-life (t1/2) of 177Lu-ACT319 in blood
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Elimination half-life derived from blood radioactivity measurements following administration of 177Lu-ACT319.

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A): Cumulative amount of 177Lu-ACT319 excreted in urine (Ae).
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Culminative radioactivity excreted in urine following administration of 177Lu-ACT319 over the planned urine collection interval.

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A): Cumulative percentage of 177Lu-ACT319 excreted in urine (Ae%).
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Culminative radioactivity excreted in urine expressed as a percentage of administered radioactivity over the planned urine collection interval.

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A): Renal clearance (CLR) of 177Lu-ACT319.
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Renal Clearance derived from urinary radioactivity excretion and corresponding blood radioactivity exposure following administration of 177Lu-ACT319

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A)
Ramy czasowe: Cycle 1: up to Day 8 post-dose.

Radioactivity uptake in normal organs and tumor lesions.

Cycle 1: up to Day 8 post-dose.
Dose escalation (Part 1A)
Ramy czasowe: Cycle 1: Up to Day 8

Tumor-to-background ratio defined as the ratio of the lesion SUV over the reference region SUV.

Cycle 1: Up to Day 8
Dose optimization and expansion (Part 2A and 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Type, frequency and severity of AEs and SAEs using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

Up to 24 months from the first treatment cycle administration.
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in systolic blood pressure
Ramy czasowe: Up to 24 months from the first treatment cycle administration

Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg).

Up to 24 months from the first treatment cycle administration
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in diastolic blood pressure
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg).

Up to 24 months the first treatment cycle administration.
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in pulse rate.
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in pulse rate, measured in beats per minute.

Up to 24 months the first treatment cycle administration.
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in respiratory rate
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in respiratory rate, measured in breaths per minute.

Up to 24 months the first treatment cycle administration.
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in body temperature
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in body temperature, measured in degrees Celsius.

Up to 24 months the first treatment cycle administration.
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG heart rate
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in heart rate, recorded using a 12-lead electrocardiogram (ECG) and measured in beats per minute.

Up to 24 months the first treatment cycle administration.
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG PR interval,
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in PR interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 24 months the first treatment cycle administration.
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG QRS duration.
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in QRS duration, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 24 months the first treatment cycle administration.
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG QT interval.
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in QT interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 24 months the first treatment cycle administration.
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in Fridericia-corrected QT interval (QTcF).
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in QT interval corrected for heart rate using Fridericia's formula, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

Up to 24 months the first treatment cycle administration.
ECOGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECOG performance status
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance-status score.

Up to 24 months the first treatment cycle administration.
Dose optimization and expansion (Parts 2A and 2B): Number of participants with clinically significant laboratory abnormalities.
Ramy czasowe: Up to 24 months the first treatment cycle administration.

Number of participants with at least one new or worsened clinically significant abnormality from baseline in hematology, biochemistry, coagulation or urinalysis. Each participant is counted once regardless of the number of qualifying abnormalities or assessment visits.

Up to 24 months the first treatment cycle administration.
Dose optimization and expansion (Part 2A and 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Frequency and duration of dose delays, dose interruptions, and dose reductions.

Up to 24 months from the first treatment cycle administration.
Dose optimization and expansion (Part 2A and 2B)
Ramy czasowe: up to 12 months after last cycle.

Progression Free Survival (PFS) determined as the time from C1D1 to the date of progression, defined as the first documented progression as per RECIST v1.1 or death for any cause.

up to 12 months after last cycle.
Dose optimization and expansion (Part 2A and 2B)
Ramy czasowe: Up to 24 months from the first treatment cycle administration.

Overall Survivor (OS) defined as the time from C1D1 to death from any cause

Up to 24 months from the first treatment cycle administration.
Dose optimization and expansion (Part 2A and 2B)
Ramy czasowe: Up to 12 months.

Disease control Rate (DCR) defined as the percentage of participants who have achieved CR, PR, or SD.

Up to 12 months.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

25 października 2026

Zakończenie podstawowe (Szacowany)

31 lipca 2029

Ukończenie studiów (Szacowany)

2 listopada 2031

Daty rejestracji na studia

Pierwszy przesłany

20 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 listopada 2026

Pierwszy wysłany (Rzeczywisty)

17 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj